معرفی
Andrew Watts serves as a Senior Lecturer in the Department of Life Sciences within the Faculty of Science at the University of Bath, where he also directs Knowledge Exchange initiatives. Based at the Centre for Therapeutic Innovation, he actively supervises doctoral students and leads interdisciplinary research at the chemistry-biology interface.
His educational foundation includes:
- PhD in Organic Chemistry from the University of Western Australia (2001)
- BSc in Organic Chemistry from the University of Western Australia (1996)
Watts' research program develops novel chemical methodologies to advance biological therapeutics, with particular emphasis on:
- Small molecule covalent enzyme inhibitors for disease treatment
- Mono-alkylating bioconjugation for antibody-drug conjugates
- Disulphide re-bridging strategies for multi-specific antibodies
- Controlling monoclonal antibody effector functions
- Targeted RNA therapeutic delivery systems
- Expanding bioconjugate modalities for clinical applications
Analysis of his 2022-2025 publications reveals a cohesive research trajectory centered on precision bioconjugation techniques. His work consistently advances antibody stabilization under thermal stress, develops site-selective protein labeling methods, and creates electrochemical biosensors for cancer diagnostics – demonstrating strong translational potential in oncology and diabetes therapeutics.
While no specific scientific awards are documented in the provided materials, Watts maintains significant research leadership through:
- Principal investigator roles in EPSRC and Innovate UK-funded projects
- Industry collaborations with healthcare and pharmaceutical partners
- Active contribution to UN Sustainable Development Goals in health innovation
He has supervised 9 graduate students and currently accepts new doctoral candidates. His project portfolio includes 12 research initiatives (1 active, 11 completed), featuring the ongoing EPSRC project Increasing capacity in the NHS (2024-2028) and multiple industry partnerships like the KTP with Qualasept Limited. Watts' research group operates within the Centre for Therapeutic Innovation, focusing on chemical solutions for unmet medical needs through robust academic-industry-government collaboration.
